| Literature DB >> 17156420 |
Milo A Puhan1, Irene Soesilo, Gordon H Guyatt, Holger J Schünemann.
Abstract
BACKGROUND: Combining outcomes and the use of standardized effect measures such as effect size and standardized response mean across instruments allows more comprehensive meta-analyses and should avoid selection bias. However, such analysis ideally requires that the instruments correlate strongly and that the underlying assumption of similar responsiveness is fulfilled. The aim of the study was to assess the correlation between two widely used health-related quality of life instruments for patients with chronic obstructive pulmonary disease and to compare the instruments' responsiveness on a study level.Entities:
Mesh:
Year: 2006 PMID: 17156420 PMCID: PMC1712224 DOI: 10.1186/1477-7525-4-94
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Figure 1Study flow from electronic database searches to final inclusion of eligible studies.
Characteristics of included studies
| Study groups | Number of patients | Intervention | Wks of follow-up | Study design | Mean baseline scores (SD) | Mean change scores (SD) | Order of questionnaires randomized | Use of validated questionnaires | ||
| Barr [18] | 102 | Respiratory rehabilitation (RP) | 4 | Prospective follow-up study | 3.89 (0.89) | 55.8 (17.9) | 0.71 (0.75) | -3.00 (12.20) | No | Yes |
| Bestall [14] | 23 | RP | 52 | RCT | 4.00 (0.90) | 51.0 (13.7) | 0.35 (0.85) | -3.00 (12.20) | No | Yes |
| Bestall [14] | 21 | Patient education | 52 | RCT | 4.28 (0.98) | 51.9 (13.9) | -0.05 (0.58) | -1.00 (9.35) | No | Yes |
| Bourbeau [22] | 65 | RP | 2 | Prospective follow-up study | n.a. | n.a. | 0.74 (0.74) | -7.20 (12.30) | Yes | Yes |
| Bourbeau [22] | 27 | Usual care | 2 | Prospective follow-up study | n.a. | n.a. | 0.35 (0.31) | -2.40 (5.57) | Yes | Yes |
| Connor [16] | 170 | RP | 52 | Prospective follow-up study | n.a. | 51.6 (15.8) | n.a. | n.a. | No | Yes |
| Desikan [23] | 40 | Usual care | 12 | Prospective follow-up study | 3.75 (0.95) | 50.2 (18.5) | 0.33 (0.86) | -2.51 (9.71) | Yes | Yes |
| de Torres [19] | 37 | RP | 8 | Prospective follow-up study | 4.13 (0.95) | 52.0 (13.0) | 0.56 (1.20) | -4.00 (13.40) | No | Yes |
| Griffiths [20] | 37 | RP | 52 | RCT | 3.59 (0.95) | 64.9 (12.7) | 0.25 (0.80) | -3.40 10.86) | No | Yes |
| Griffiths [20] | 33 | Usual care | 52 | RCT | 3.53 (0.95) | 68.3 (13.3) | -0.08 (0.80) | 0.70 (10.86) | No | Yes |
| Hajiro [24] | 165 | Usual care | 12 | Prospective follow-up study | 5.31 (0.97) | 40.3 (20.1) | 0.65 (0.83) | -6.00 (18.50) | No | Yes |
| Harper [25] | 156 | Usual care | 26 | Prospective follow-up study | 3.69 (0.95) | 65.4 (15.9) | 0.07 (1.00) | 0.81 (9.95) | No | Yes |
| Man [17] | 21 | RP | 18 | RCT | 2.64 (0.95) | 65.4 (13.5) | 1.87 (0.53) | -16.10 (5.95) | No | Yes |
| Man [17] | 21 | Usual care | 16 | RCT | 3.11 (0.95) | 69.6 (13.6) | 0.49 (0.26) | -3.40 (8.50) | No | Yes |
| Rutten [9] | 47 | Salmeterol + Ipratropium | 12 | RCT | 4.44 (0.81) | 48.3 (13.9) | 0.20 (0.60) | -2.40 (11.00) | No | Yes |
| Rutten [9] | 47 | Salmeterol + Placebo | 12 | RCT | 4.58 (1.03) | 50.5 (16.6) | -0.19 (0.80) | -0.01 (7.10) | No | Yes |
| Rutten [9] | 50 | Placebo | 12 | RCT | 4.22 (1.05) | 50.2 (15.8) | 0.03 (0.70) | 0.50 (9.20) | No | Yes |
| Singh [12] | 97 | RP | 7 | Prospective follow-up study | 3.66 (0.92) | 58.8 (15.2) | 0.72 (1.00) | -4.02 (12.98) | No | Yes |
| Schunemann [8] | 84 | RP | 12 | Prospective follow-up study | 4.01 (0.95) | 52.8 (13.9) | 1.14 (0.90) | -8.10 (20.40) | Yes | Yes |
| Schunemann [10] | 183 | RP | 12 | Prospective follow-up study | 4.57 (0.95) | 50.6 (13.9) | 0.55 (0.89) | -5.43 (11.18) | Yes | Yes |
| Wedzicha [15] | 26 | RP on | 8 | RCT | 3.76 (0.90) | 56.7 (14.0) | 0.20 (0.39) | 3.00 (10.40) | No | Yes |
| Wedzicha [15] | 28 | Patient education | 8 | RCT | 3.82 (1.20) | 59.1 (13.0) | 0.20 (0.32) | 2.00 (8.10) | No | Yes |
RCT: Randomized controlled trial; n.a.: not available
Figure 2Scatter plots of CRQ and SGRQ change scores from 21 groups where patients completed both the CRQ and SGRQ.
Figure 3Box plots showing the distributions of standardised response means for the CRQ and SGRQ. Boxes display the interquartile range and the median while the whiskers show 95% of the data. Asterisks indicate an outlier study group [17] that showed much larger change scores that the other studies.